Erratum: ERRATUM: OPTIMA: a phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer (Ann Oncol (2019) DOI: 10.1093/annonc/mdy522)

T. Y. Seiwert, C. C. Foster, E. A. Blair, T. G. Karrison, N. Agrawal, J. M. Melotek, L. Portugal, R. J. Brisson, A. Dekker, S. Kochanny, Z. Gooi, M. W. Lingen, V. M. Villaflor, D. T. Ginat, D. J. Haraf, E. E. Vokes

Research output: Contribution to journalComment/debatepeer-review

Abstract

In the original article, the wrong supplementary material was accidentally uploaded. This has now been corrected. The Publisher apologizes for the error.

Original languageEnglish (US)
Pages (from-to)1673
Number of pages1
JournalAnnals of Oncology
Volume30
Issue number10
DOIs
StatePublished - Oct 1 2019

ASJC Scopus subject areas

  • Hematology
  • Oncology

Fingerprint

Dive into the research topics of 'Erratum: ERRATUM: OPTIMA: a phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer (Ann Oncol (2019) DOI: 10.1093/annonc/mdy522)'. Together they form a unique fingerprint.

Cite this